Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication

Table 1 Baseline demographic and clinical characteristics

Characteristic	BOACT (n = 104)	BOTMO (n = 104)
Male/Female	32/72	39/65
Age (yr)	41.6 ± 12.2	39.6 ± 11.8
Smoking, n (%)
Yes	28 (26.9)	27 (26.0)
No	76 (73.1)	77 (74.0)
Initial eradication regimen, n (%)
BOAC	82 (78.8)	75 (72.1)
BOAM	22 (21.2)	29 (27.9)

BOAC: Bismuth subcitrate, omeprazole, amoxicillin, clarithromycin; BOACT: Bismuth subcitrate, omeprazole, amoxicillin, clarithromycin, tinidazole; BOAM: Bismuth subcitrate, omeprazole, amoxicillin, metronidazole; BOTMO: Bismuth subcitrate, omeprazole, tetracycline, metronidazole, ofloxacin.

Table 2 Reported side effects n (%)

Side effect	Regimen
	BOACT (n = 1021)	BOTMO (n = 1032)
Headache	17 (17.6)a	7 (7.8)
Taste disturbance	14 (15.7)a	6 (5.8)
Nausea	5 (4.9)	3 (2.9)
Epigastric pain	4 (3.9)	2 (1.9)
Diarrhea	4 (3.9)	2 (1.9)
Heartburn	3 (2.9)	2 (1.9)
Stool color change	3 (2.9)	2 (1.9)
Urine color change	2 (1.9)	1 (0.9)
Anorexia	3 (2.9)	1 (0.9)
Total	55 (77.4)b	26 (36.6)

¹Two and

²one of the patients from the group discontinued treatment due to severe adverse effects.

^aP < 0.05,

^bP < 0.01 vs control. BOACT: Bismuth subcitrate, omeprazole, amoxicillin, clarithromycin, tinidazole; BOTMO: Bismuth subcitrate, omeprazole, tetracycline, metronidazole, ofloxacin.